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LSDs and 5.6% for RSP (p = 0.52) and the overall post-
operative complication rate was 28.6% for LSDs and 
34.9% for RSP (p = 0.40). For both URSs and PNLs, no 
statistically significant differences in complication grade 
scores were observed between LSDs and RSP. Operation 
time was significantly longer for LSD-URS group, but 
there was no difference between the PNL groups. There 
were no significant differences in length of hospital stay 
and stone-free rate. The retreatment rate was higher in the 
LSD-URS group compared with RSP-URS group but simi-
lar between the PNL groups. Multiple logistic regression 
analyses, adjusting for confounders, revealed no associa-
tion between LSD and more or less favourable outcomes as 
compared to RSP.
Conclusion Live surgical demonstrations do not seem to 
compromise patients’ safety and outcomes when performed 
by specialised endourologists.
Keywords Stones · Live · Surgical · Demonstrations · 
Ureteroscopy · Percutaneous · Lithotomy · Urolithiasis
Abbreviations
ALS  As live surgery
ECIRS  Endoscopic combined intrarenal surgery
LSD  Live surgical demonstration
RSP  Routine surgical practice
SSA  Stone surface area
Introduction
Live surgical demonstrations (LSDs) are a popular educa-
tional tool. With the increased prevalence and popularity of 
LSDs, their educational value, professional and financial 
conflicts of interest and, above all, patients’ safety have 
Abstract 
Purpose To compare intra- and post-operative outcomes 
of endourological live surgical demonstrations (LSDs) and 
routine surgical practice (RSP) for urinary stones.
Methods Consecutive ureterorenoscopic (URS) and per-
cutaneous (PNL) urinary stone procedures over a 5-year 
period were reviewed. Procedures were divided into LSDs 
and RSP. Differences between the groups were separately 
analysed for URS and PNL. Primary outcomes included 
intra- and post-operative complication rates and grades. 
Secondary outcomes were operation time, length of hospi-
tal stay, stone-free rate, and retreatment rate. Pearson’s Chi-
square analysis, Mann–Whitney U test, and logistic and 
linear regression were used to compare outcomes between 
LSDs and RSP.
Results During the study period, we performed 666 URSs 
and 182 PNLs, and 151 of these procedures were LSDs. 
Among URSs, the overall intra-operative complication 
rate was 3.2% for LSDs and 2.5% for RSP (p = 0.72) and 
the overall post-operative complication rate was 13.7% 
for LSDs and 8.8% for RSP (p = 0.13). Among PNLs, 
the overall intra-operative complication rate was 8.9% for 
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been questioned [1, 2]. To secure patients’ safety, several 
surgical societies have published policy statements for the 
performance of LSDs [3]. The European Association of 
Urology (EAU) published a policy, which provides sup-
portive information on how to organise and safely con-
duct LSDs. The paramount principle of this policy is that 
patients’ safety has top priority over all other considerations 
[1]. Furthermore, the literature about the safety of LSDs in 
the urological field is quite scarce. Most of the studies con-
ducted are policy publications or surveys [1, 3–6] and the 
conclusions of these studies are not based on observations 
or treatment outcomes.
To obtain more objective information about patients’ 
safety during LSDs, insight in the surgical outcomes of 
these procedures is needed. The objective of this study 
is to evaluate possible differences in outcomes between 
endourological stone removal procedures performed during 
LSDs and during routine surgical practice (RSP).
Material and methods
Outcomes
Primary outcomes included intra-operative complication 
rates and post-operative complication rates and Clavien–
Dindo grades. Secondary outcomes were operation time, 
length of hospital stay, stone-free rates, and retreatment 
rates.
Data collection, definitions, and setting
Data were retrospectively collected from all consecu-
tive endoscopic procedures performed for urinary stones 
in the academic center of the leading author from Janu-
ary 2011 through July 2015. Procedures were divided into 
ureterorenoscopic (URS) and percutaneous procedures. 
Percutaneous procedures included percutaneous nephro-
lithotomy (PNL) and endoscopic combined intrarenal sur-
gery (ECIRS). Within these two groups, procedures were 
divided into cases performed as LSDs and RSP. An LSD 
was defined as a surgical procedure performed in real time 
and observed for educational purposes [1]. At our academic 
hospital, LSDs have been done since 2005. During the 
study period, we performed 151 LSDs, organized as fol-
lows. Visitors participated in a 2-day course. On the first 
day, lectures were given. The second day visitors watched 
LSDs via a live broadcast in the hospital or they were pre-
sent in the operation room. During the surgery, there was a 
two-way connection to communicate with the surgeon or 
moderators. Courses had an international setting with par-
ticipating visitors and surgeons from different countries. 
The language of communication was English. Surgeons 
were specialised endourologists from our own institution or 
guest surgeons with extensive experience in endourology. 
Guest surgeons were familiar with the equipment and envi-
ronment of the operating theatres. Surgery performed by 
a guest surgeon was always accompanied by one or more 
endourologists from our own institution.
Study population and selection
Patients included in this study were all patients who under-
went endourological stone removal during the study period. 
During LSDs, a combination of high and low complexity 
cases was selected, depending on the available patients. 
Patients operated in LSDs were well informed about the 
theatre setting and guest surgeons. All patients signed an 
informed consent.
Data collection
Patient’s demographic and clinical characteristics were 
assessed. Total stone burden was computed as the 
stone surface area (SSA) on imaging with the formula: 
length*width*0.25*π [7, 8].
The SSA was computed on the CT scan transverse slice 
in which the stone appeared the widest. In case of multiple 
stones, the sum of the single SSAs was computed.
Outcomes and follow‑up
Intra-operative complications included: bleeding, perfora-
tion, ureteral damage, avulsion, and complications outside 
the urinary tract. Post-operative complications were: bleed-
ing, fever (>38.0 °C), urinary tract infection, sepsis, pain 
needing intervention, urinary leakage, death, and complica-
tions outside the urinary tract. Post-operative complications 
were classified according to the Clavien–Dindo classifica-
tion [9]. For PCNL, the validated Clavien score for percuta-
neous nephrolithotomy was used [10].
Failure of the procedure was defined as failed access to 
the ureter or the collecting system, leaving the stone in situ. 
Operation time was defined as the time interval between 
the introduction and the extraction of the scope for URS 
and from the puncture to the positioning of the nephros-
tomy for PNLs. In case of tubeless PNLs, the extraction of 
the scope and the Amplatz sheath was considered the end 
of the procedure. The total follow-up period was 3 months. 
The stone-free status was assessed with ultrasound or com-
puted tomography at 6–8 weeks after the procedure. Stone-
free was defined as the absence of fragments >1 mm on CT 
or total absence of fragments on ultrasound. In the absence 
of post-operative imaging, intra-operative confirmation 
with the absence of stones >1 mm was applied to meet a 
stone-free status.
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Statistical analysis
Comparative analysis was performed using Pearson’s Chi-
square or Fisher’s exact test for categorical variables and 
Mann–Whitney U test for not normally distributed continu-
ous variables. Multiple linear and logistic regression anal-
yses were performed to analyse the association between 
LSD and outcomes as they differed from RSP. Outcomes 
were adjusted for confounders. The confounding variables 
for URS were stone burden, renal anomalies, stone loca-
tion. A confounding factor for PNL was the stone burden. 
For all analyses, the level of statistical significance was set 
at p < 0.05. All calculations were performed using IBM 
SPSS 23.0.
Results
Patient and procedure characteristics
We included 666 URS and 182 percutaneous procedures. In 
the URS group, 95 (14.3%) procedures were LSDs. In the 
percutaneous procedures group, 56 (30.8%) were LSDs. 
Tables 1 and 2 present baseline characteristics of patients 
operated during LSDs and RSP, which were well matched 
for both groups, with the exception of the amount of renal 
anomalies which was significantly higher in the LSD-URS 
group as compared with the RSP-URS group.
Tables 3 and 4 present pre-operative clinical informa-
tion. For URS, the median SSA was 91 mm2 in the LSDs 
group and 48 mm2 in the RSP group (p < 0.001). In LSDs, 
the stone was located in the kidney in 84.2%, while in 
RSP in 49.7% (p < 0.001) of the cases. There was no sig-
nificant difference in pre- and post-operative ureteral stent 
placement.
In the percutaneous procedures group, the average SSA 
was 389 mm2 for LSDs and 280 mm2 for RSP (p = 0.0.39). 
Patients had stones in multiple anatomical locations of the 
kidney or ureter in 51.8% of the LSDs and in 42.9% of the 
RSP procedures. An ECIRS was performed in 83.9% of the 
LSDs and in 34.9% of the RSP procedures (p < 0.001).
Ureteroscopic procedures
Descriptive data on complications and secondary outcomes 
for URS procedures are presented in Table 5. There were 
no significant differences either in the overall intra-opera-
tive complication rates (3.2% for LSDs vs. 2.5% for RSP, 
p = 0.72) or in the overall post-operative complication 
rates (13.7% for LSDs vs. 8.8% for RSP, p = 0.13). The 
majority of the complications were classified as Clavien 2 
in both groups. In both groups, one Clavien 5 complication 
occurred.
The median operation time was 50 min in the LSD 
group and 41 min in the RSP group (p < 0.001). The 
median length of hospital stay was 1 day in both groups. 
The stone-free rate was 63.0% in the LSD group and 67.7% 
in the RSP group (p = 0.39). A retreatment was needed in 
18.9% of LSDs and 11.2% of RSP procedures (p = 0.034).
Percutaneous procedures
Descriptive data on complications and secondary outcomes 
for percutaneous procedures are presented in Table 6.
There were neither significant differences in the over-
all intra-operative complication rates (8.9% for LSDs vs. 
5.6% for RSP, p = 0.052) nor in the overall post-operative 
complication rates (28.6% for LSDs vs. 34.9% for RSP, 
p = 0.40). There were no significant differences in Clavien 
complication grades between the groups. One Clavien 5 
complication occurred in the RSP group.
Operation time did not significantly differ between LSDs 
and RSP. The median length of hospital stay was 4 days 
after LSDs and 3 days after RSP procedures (p = 0.086). 
The stone-free rate was 50.0% in the LSD group and 38.5% 
in the RSP group (p = 0.16). After LSDs, 25.5% of the 
patients required retreatment compared with 36.0% after 
RSP procedures (p = 0.16).
Regression models
For both URS and PNL, the model revealed no association 
between the factors in LSDs and higher intra- and post-
operative complications, longer hospital stay, lower stone-
free rates, higher retreatment rates, and longer operation 
times. The complete univariate and multivariate models can 
be found in Table S1 of the supplementary material.
Discussion
The most important finding of this study is that we did not 
observe major statistically significant differences either in 
overall intra-operative or in post-operative complication 
rates and grades between LSDs and RSP for urinary stones.
We observed higher complication rates for LSDs then 
for RSP in the URS group, but the difference is not statisti-
cally significant and can be explained by external factors. 
The median stone burden in LSDs was almost twice as 
large as in RSP. The regression model supports that this has 
contributed to the longer operation time of LSDs. Further-
more, in the LSD group, the percentage of kidney stones 
was higher than in the RSP group and complication rates 
in URS are higher in case of renal stones than of ureteral 
stones [11, 12]. In addition, the percentage of patients with 
renal anomalies was higher in the LSD group. The presence 
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Table 1  Baseline characteristics of ureteroscopy for stones
Statistical tests: A) Pearson’s Chi-square test, B) Fisher’s exact test, and C) Mann–Whitney U test. Data are n (%) of patients for whom data 
were available. Percentages exclude missing values from denominators
ASA American Society of Anesthesiologists, DM diabetes mellitus, CVD cardio vascular disease, PCNL percutaneous nephrolithotomy, ESWL 
extra corporeal shockwave lithotripsy, URS ureterorenoscopy, UPJ uretero-pelvic junction, NS not significant
Characteristics All procedures n = 666 LSD-URS n = 95 (14.3) RSP-URS n = 571 (85.7) p value Test
Age, median in years [IQR] 53, [40–65] 53, [39–61] 53, [40–65] 0.56 C
(n = 666) (n = 95) (n = 571)
Gender
 Male, n (%) 423 (63.5) 57 (60.0) 366 (64.1) 0.44 A
 Female, n (%) 243 (36.5) 38 (40.0) 205 (35.9)
(n = 666) (n = 95) (n = 571)
BMI median [IQR] 26.0, [23.8–9.0] 25.9, [24.2–29.6] 26.0, [23.7–29.0] 0.57 C
(n = 652) (n = 91) (n = 561)
ASA score, n (%)
 I 242 (36.3) 37 (38.9) 205 (35.9) 0.85 A
 II 336 (50.5) 45 (47.4) 291 (51.0)
 III 86 (12.9) 13 (13.7) 73 (12.8)
 IV 2 (0.3) 0 (0) 2 (0.4)
(n = 666) (n = 95) (n = 571)
Comorbidity and medication, n (%)
 DM 90 (13.5) 16 (17.8) 74 (13.0) 0.31 A
(n = 665) (n = 95) (n = 570)
 CVD 245 (36.8) 30 (31.6) 215 (37.7) 0.25 A
(n = 665) (n = 95) (n = 570)
 Crohn’s disease 20 (3.0) 0 (0) 20 (3.4) 0.096 B
(n = 665) (n = 95) (n = 570)
 Prednisone 30 (4.5) 4 (4.2) 26 (4.6) 1.0 B
(n = 665) (n = 95) (n = 570)
 Anticoagulation 117 (17.6) 11 (9.4) 106 (18.6) 0.096 A
(n = 665) (n = 95) (n = 570)
Previous stone treatment in the same renal unit, n (%)
 URS 253 (38.0) 43 (45.3) 210 (36.8) 0.12 A
(n = 666) (n = 95) (n = 571)
 PCNL 87 (13.1) 20 (21.1) 67 (11.7) 0.013 A
(n = 666) (n = 95) (n = 686)
 SWL 123 (15.9) 20 (19.6) 82 (14.4) 0.087 A
(n = 663) (n = 95) (n = 569)
 Ureterolithotomy 6 (0.9) 0 (0) 6 (1.1) 0.60 B
(n = 666) (n = 95) (n = 571)
 Pyelolithomy 8 (1.2) 4 (4.2) 4 (0.7) 0.017 B
(n = 665) (n = 95) (n = 570)
Anatomical variant
 Anomalies 37 (5.6) 11 (11.6) 26 (4.6) 0.006 A
(n = 666) (n = 95) (n = 571)
 Solitary kidney 16 (2.4) 2 (2.1) 14 (2.5) 1.00 B
(n = 666) (n = 95) (n = 571)
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Table 2  Baseline characteristics of percutaneous stone procedures
Statistical test: A) Pearson’s Chi-square test, B) Fisher’s exact test, and C) Mann–Whitney U test. Data are n (%) of patients for whom data were 
available. Percentages exclude missing values from denominators
ASA American Society of Anesthesiologists, DM diabetes mellitus, CVD cardio vascular disease, PCNL percutaneous nephrolithotomy, ESWL 
extra corporeal shockwave lithotripsy, URS ureterorenoscopy, NS not significant
Characteristics All procedures  
n = 182
LSD percutaneous  
n = 56 (30.8)
RSP percutaneous  
n = 126 (69.2)
p value Test
Age, median in years [IQR] 51, [36–66] 53.5, [38–67] 51, [34–65] 0.30 C
(n = 182) (n = 56) (n = 126)
Gender
 Male, n (%) 107 (58.8) 29 (51.8) 78 (61.9) 0.20 A
 Female, n (%) 75 (41.2) 27 (48.2) 48 (38.1)
(n = 182) (n = 56) (n = 126)
BMI, median [IQR] 25.6, [22.8–28.2] 25.1, [22.4–27.9] 25.6, [23.1–28.4] 0.43 C
(n = 179) (n = 56) (n = 123)
ASA score, n (%)
 I 55 (30.2) 19 (33.9) 36 (28.6) 0.39 A
 II 101 (55.5) 27 (48.2) 74 (58.7)
 III 26 (14.3) 10 (17.9) 16 (12.7)
 IV 0 (0) 0 (0) 0 (0)
(n = 182) (n = 56) (n = 126)
Comorbidity and medication, n (%)
 DM 18 (9.9) 5 (8.9) 13 (10.3) 1.00 B
(n = 182) (n = 56) (n = 126)
 CVD 79 (43.4) 23 (41.4) 56 (44.4) 0.67 A
(n = 126) (n = 56) (n = 126)
 Crohn’s disease 3 (1.6) 0 (0) 3 (2.4) 0.55 B
(n = 126) (n = 56) (n = 126)
 Prednisone 14 (7.7) 2 (3.6) 12 (9.5) 0.23 B
(n = 126) (n = 56) (n = 126)
 Anticoagulation 29 (15.9) 11 (19.6) 18 (14.3) 0.36 A
(n = 128) (n = 56) (n = 126)
 Previous stone treatment, n (%) 107 (58.8) 32 (57.1) 75 (59.5) 0.76 A
In the same renal unit (n = 182) (n = 56) (n = 126)
 SWL 37 (20.3) 12 (21.4) 25 (19.8) 0.81 A
(n = 182) (n = 56) (n = 126)
 URS 33 (18.1) 12 (21.4) 21 (16.7) 0.44 A
(n = 182) (n = 56) (n = 126)
 PCNL 55 (30.2) 13 (23.2) 42 (33.3) 0.17 A
(n = 182) (n = 56) (n = 126)
 ECIRS 24 (13.2) 10 (17.9) 14 (11.1) 0.24 B
(n = 182) (n = 56) (n = 126)
 Pyelolithomy 9 (4.9) 3 (5.4) 6 (4.8) 1.00 B
(n = 182) (n = 56) (n = 126)
Anatomical variant
 Renal anomalies, n (%) 9 (4.9) 4 (7.1) 5 (4.0) 0.46 B
(n = 182) (n = 56) (n = 126)
 Solitary kidney, n (%) 5 (2.7) 2 (3.6) 3 (2.4) 0.64 B
(n = 182) (n = 56) (n = 126)
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of a renal anomalies was previously be found to be a factor 
affecting complication rates [13].
The majority of post-operative complications in both 
URS- and PNL-LSD groups were classified as Clavien 1 
or 2 and no invasive intervention was needed. However, in 
both the URS-LSD and the URS-RSP groups, one Clavien 5 
complication occurred. In the LSD group, this concerned an 
85-year-old patient who was in a poor pre-operative condi-
tion. The patient was admitted with an obstructive distal ure-
teral stone that caused urinary tract infection, hydronephrosis, 
and severe delirium. A percutaneous renal drain was placed 
and antimicrobial treatment was started. After admittance 
for 22 days in the hospital, an uncomplicated URS was per-
formed. The post-operative course was complicated by auto-
nomic dysregulation without a plausible reason. 26 days after 
surgery, an aspiration pneumonia with further deterioration 
of clinical conditions led to the decision to follow a palliative 
setting. In this study, the characteristics of patients operated 
during LSDs and RSP were comparable. Therefore, patients 
selected for LSDs are representative of the usual cases we 
treat in our stone referral centre. In this particular case, we 
do not feel that we could have prevented these complica-
tions by operating this patient during RSP. Due to the rela-
tively high frequency of LSDs in our centre, it happens that 
also more fragile patients are operated on LSD days. In some 
cases, patients are scheduled in a semi-emergency setting 
during LSD. This way, we also shorten their waiting time for 
surgery. In this described case, the patient was admitted for a 
long period and was being worked up for surgery.
In the RSP group. a Clavien V complication occurred 
in a 88-year-old ASA 3 patient with a medical history 
a hypophysis tumour, multiple CVAs with a left sided 
Table 3  Operation data of ureteroscopy for stones
Statistical tests: A) Pearson’s Chi-square test, B) Fisher’s exact test, and C) Mann–Whitney U test
* Nephrostomy tube and a double J stent or ureteral catheter. Data are n (%) of patients for whom data were available. Percentages exclude miss-
ing values from denominators
Outcomes LSD-URS n = 95 (14.3) RSP-URS n = 571 (85.7) p value Test
Total stone burden  (mm2) median,[IQR] 91, [44–192] 48, [25–87] 0.001 C
(n = 95) (n = 558)
General stone location
 Kidney 80 (84.2) 284 (49.7) 0.001 A
 Ureter 11 (11.6) 235 (41.2)
 Kidney and ureter 4 (4.2) 52 (9.1)
(n = 95) (n = 571)
Kidney stone location, n (%)
 Renal pelvis 12 (15.0) 48 (16.9) 0.93 A
 Upper calix 5 (6.3) 17 (6.0)
 Middle calix 8 (10.0) 26 (9.2)
 Lower calix 26 (32.5) 103 (36.3)
 Multiple 29 (36.3) 90 (31.7)
(n = 80) (n = 284)
Ureteral location, n (%)
 Proximal 3 (27.3) 83 (35.3) 0.25 A
 Mid 2 (18.2) 45 (19.1)
 Distal 5 (45.5) 104 (44.3)
 Multiple 1 (9.1) 3 (1.3)
(n = 11) (n = 235)
Pre-operative ureteral stent, n (%) 28 (29.5) 174 (30.5) 0.84 A
(n = 95) (n = 571)
Exit strategy
 Double J stent 52 (54.7) 283 (49.6) 0.19 A
 Ureteral catheter 27 (28.4) 156 (27.3)
 Nephrostomy tube 1 (1.1) 10 (1.8)
 Ureteral stent and nephrostomy 5 (5.3) 14 (2.5)
 Tubeless 10 (10.5) 108 (18.9)
(n = 95) (n = 571)
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hemiparesis, renal insufficiency due to hypertension and 
ischemia after an acute myocardial infarction which, 
together with a severe aortic valve stenosis, resulted in a 
very poor cardiac function. After the complete resolution 
of a urosepsis due to an obstructive ureteral stone, a URS 
with stone disintegration was performed. Despite perioper-
ative antibiotic prophylaxis, based on previous cultures, the 
patient post-operatively developed a urosepsis with cardiac 
decompensation. Support of intensive care initially attained 
sufficient clinical progression. However, after another flair 
of urosepsis with severe cardiac decompensation in an 
elderly highly morbid patient, it was decided to follow a 
palliative setting 20 days after the surgery.
The mortality rate of 2:666 cases in this cohort is high. 
In both cases, the pros and cons of alternative options for 
URS were balanced accurately in a team of staff members 
and with the patients. These cases reflect the highly com-
plex situations we sometimes face, in which, unfortunately, 
severe complications can occur.
We observed some differences between the LSD and 
the RSP groups for what concerns the secondary out-
comes of this study. The longer operation time and the 
higher retreatment rate for URS-LSDs can be explained 
by the larger median stone burden compared to RSP pro-
cedures. Moreover, LSDs represent educational moments 
and the surgeon is expected to explain and respond to 
Table 4  Surgical data of percutaneous stone procedures
Statistical test: A) Pearson’s Chi-square test, B) Fisher’s exact test, and C) Mann–Whitney U test. Data are n (%) of patients for whom data were 
available. Percentages exclude missing values from denominators
ECIRS endoscopic combined intrarenal surgery
* Ureter included
** Including ureteral stent and double J catheter
*** Including prone and supine
Outcomes LSD percutaneous n = 56 (30.8) RSP percutaneous n = 126 (69.2) p value Test
Total stone burden  (mm2) median, [IQR] 389, [228–676] 280, [132–595] 0.039 C
(n = 54) (n = 107)
Total stone diameter, median in mm, [IQR] 41 [27–66] 28 [18–68] 0.063 C
(n = 54) (n = 108)
Density in hounsfield units, median, [IQR] 950, [678–1189] 900, [661–1020] 0.22 C
(n = 45) (n = 101)
Stone location, n (%)
 Renal pelvis 10 (17.9) 17 (13.5) 0.14 A
 Upper calix 0 (0) 8 (6.3)
 Middle calix 1 (1.8) 2 (1.6)
 Lower calix 8 (14.3) 21 (16.7)
 Staghorn stone 8 (14.3) 14 (11.1)
 Ureteral stone 0 (0) 10 (7.9)
 Multiple locations* 29 (51.8) 54 (42.9)
(n = 56) (n = 126)
Pre-operative ureteral stent n (%) 9 (16.1) 19 (15.1) 0.83 B
(n = 56) (n = 126)
Pre-operative percutaneous drain n (%) 6 (10.7) 27 (21.4) 0.098 B
(n = 56) (n = 126)
Exit strategy
 Ureteral stent** 5 (8.9) 8 (6.5) 0.31 A
 Nephrostomy tube 28 (50.0) 78 (63.4)
 Ureteral stent and nephrostomy 23 (41.1) 36 (29.3)
 Tubeless 0 (0) 1 (0.8)
(n = 56) (n = 123)
Type of operation
 PNL only*** 9 (16.1) 82 (65.1) 0.001 B
 ECIRS 47 (83.9) 44 (34.9)
(n = 56) (n = 126)
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Table 5  Intra- and post-operative complications and outcomes of ureteroscopy for stones
Outcomes LSD-URS n = 95 (14.3) RSP-URS n = 571 (85.7) p value Test
Intra-operative complications, n (%)
 Overall 3 (3.2) 14 (2.5) 0.72 B
 Bleeding 1 (1.1) 3 (0.5) 0.46 B
 Perforation 0 (0) 10 (1.8) 0.37 B
 Avulsion 0 (0) 0 (0)
 Other 2 (2.1) 1 (0.2)  0.055 B
(n = 95) (n = 571)
Post-operative complications, n (%)
 Overall* 13 (13.7) 50 (8.8) 0.13 A
 Bleeding 0 (0) 3 (0.5) 1.00 B
 Fever (>38.0) 7 (7.4) 19 (3.3) 0.080 B
 UTI 5 (5.3) 17 (3.0) 0.23 B
 Sepsis 4 (4.2) 16 (2.8) 0.51 B
 Pain 0 (0) 13 (2.3) 0.23 B
 Death 1 (1.1) 1 (0.2) 0.27 B
 Other 2 (2.1) 1 (0.2) 0.21 B
(n = 95) (n = 571)
Total blood transfusion rate, n (%) 0 (0) 6 (1.1) 1.00 B
(n = 94) (n = 571)
Clavien grading score, n (%)
 None 82 (86.3) 521 (91.2) 0.12 A
 1 0 (0) 6 (1.1)
 2 11 (11.6) 31 (5.4)
 3a 0 (0) 6 (1.1)
 3b 0 (0) 3 (0.5)
 4a 1 (1.1) 3 (0.5)
 4b 0 (0) 0 (0)
 5 1 (1.1) 1 (0.2)
(n = 95) (n = 571)
Failed procedures 8 (8.4) 30 (5.3) 0.23 B
(n = 95) (n = 571)
Operation time minutes, median, [IQR] 50, [40.5–68] 41, [25–63] <0.001 C
(n = 95) (n = 570)
Post-operative length of hospital stay 1.0, [1.0–1.0] 1.0, [1.0–1.0] 0.83 C
days, median, [IQR] (n = 94) (n = 571)
Stone-free rate 58 (63.0) 366 (67.7) 0.39 A
(n = 92) (n = 541)
Method of evaluation
 Computed tomography 6 (6.3) 20 (3.5) 0.19 A
 Ultrasound 56 (58.9) 430 (75.3) <0.001 A
 Intra-operative confirmation 26 (27.4) 106 (18.6) 0.046 A
 Other 7 (7.4) 15 (2.6) 0.017 A
(n = 95) (n = 571)
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comments. This may prolong the operation time too. 
Multitasking skills are required to perform an educa-
tional but safe and effective surgery avoiding unnecessary 
extension of the operation time.
The higher stone-free rate after PNL-LSDs may be 
due to the higher rate of ECIRS performed in this setting 
compared with RSP. In LSDs, there is often the availa-
bility to utilize two surgeons who can perform a simul-
taneous antegrade and retrograde approach which could 
result in higher stone-free rates [14]. An explanation for 
the higher use of ECIRS during LSDs is the higher preva-
lence of patients with stones in multiple locations and the 
higher median stone burden.
In this study, the stone-free rates were rather unsatisfac-
tory for both PNL and URS groups. A possible explanation 
is our strict definition of stone-free status with a cutoff of 
residual fragments <1 mm. Second, the portion of failed 
procedures, which was 5.7% in the total URS group, is also 
included in this calculation. Third, we prefer to approach 
large stones in staged procedures to limit operation time 
and thereby the possible occurrence of complications. 
Finally, training and teaching situations could have had 
a negative impact on effectiveness in both LSD and RSP 
settings.
In conclusion, differences in outcomes seem to be 
explainable and the outcomes in the regression models, 
adjusted for differences between groups, were not associ-
ated with less favourable but also not to more favourable 
outcomes for LSDs.
Despite the fact that none of the differences between 
outcomes were statistically significant, we observed cer-
tain trends. For URS-LSD, there was a trend towards less 
favourable outcomes for what concerns intra- and post-
operative complications, stone-free rates, operation time, 
and retreatment rates. After adjustment for confounders, 
this trend was confirmed for post-operative complications. 
For PNL-LSD, there was a trend towards less favourable 
outcomes for what concerns intra-operative complica-
tions and operation time. After adjustment for confound-
ers, this trend was confirmed for intra-operative compli-
cations. We cannot deny these trends and we think that 
careful monitoring of future outcomes is a paramount 
consideration.
Theoretical framework
To our knowledge, there are no studies comparing the out-
comes of endourological procedures performed during 
LSDs and RSP. In the field of urology, a study by Mull-
ins et al. compared outcomes of 39 robot-assisted partial 
nephrectomy procedures performed as LSDs with 847 
procedures performed as RSP. They found no significant 
differences in operation time, warm ischemia time, posi-
tivity of surgical margin rates, and complication rates. The 
authors conclude that live robotic surgery can be performed 
safely [15].
In the field of gastroenterology, outcomes of endoscopic 
retrograde cholangiopancreatography (ERCP) performed 
as live demonstrations were compared with routine pro-
cedures. Liao et al. performed a large multicentre study 
including 406 patients that were matched with control 
patients. The overall complication rate of ERCP in LSDs 
was not significantly different from RSP. They observed 
a small but statistically significant difference in treatment 
success rates unfavourable to LSDs (94.1% vs. 97.5%, 
p = 0.021). Treatment success and complications after 
ERCP were similar if the procedures were performed by 
local faculty, domestic visiting, and foreign visiting facul-
ties [16].
With respect to complications rates, the findings of the 
above-mentioned studies are in agreement with the findings 
of this study.
Several groups evaluated patients’ safety, educational 
value and ethical issues surrounding LSDs with surveys. 
Khan et al. demonstrated higher anxiety levels in surgeons 
operating in a foreign environment. Difficult communica-
tion in the operative theatre, equipment issues, and travel-
fatigue appeared to have impact on the surgical perfor-
mance [4]. Duty et al. performed a survey investigating 90 
American Association of Genitourinary Surgeons mem-
bers. In this study, 28.2% felt moderate, 9.9% high, and 
8.5% very high anxiety levels while performing LSDs in 
Table 5  continued
Outcomes LSD-URS n = 95 (14.3) RSP-URS n = 571 (85.7) p value Test
Retreatment, n (%) 18 (18.9) 64 (11.2) 0.034 A
(n = 95) (n = 571)
Readmission <3 months, n (%) 19 (20.0) 76 (13.4) 0.088 A
(n = 95) (n = 568)
UTI urinary tract infection, KUB kidneys, ureters, bladder
* Number of procedures with post-operative complications. Per procedure more than one complication could have been scored. Statistical tests: 
A) Pearson’s Chi-square test, B) Fisher’s exact test, and C) Mann–Whitney U test. Data are n (%) of patients for whom data were available. Per-
centages exclude missing values from denominators
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Table 6  Intra- and post-operative complications and outcomes of the following percutaneous stone procedures
Outcomes LSD percutaneous n = 56 (30.8) RSP percutaneous n = 126 (69.2) p value Test
Intra-operative complications, n (%)
 Overall 5 (8.9) 7 (5.6) 0.52 B
 Bleeding* 3 (5.4) 4 (3.2) 0.68 B
 Ureteral perforation 0 (0) 2 (1.6) 1.0 B
 Mucosal damage of the ureter 1 (1.8) 1 (0.8) 0.52 B
 Ureteral avulsion 0 (0) 0 (0)
 Liver puncture 1 (1.8) 0 (0)  0.31 B
 Other 0 (0) 0 (0)
(n = 56) (n = 126)
Post-operative complications, n (%)
 Overall 16 (28.6) 44 (34.9) 0.40 A
 Bleeding 3 (5.4) 15 (11.9) 0.28 B
 Fever (>38.0) 4 (7.1) 8 (6.3) 1.00 B
 UTI 6 (10.7) 7 (5.6) 0.22 B
 Sepsis 1 (1.8) 8 (6.3) 0.29 B
 urinary leakage 3 (5.4) 2 (1.6) 0.17 B
 Death 0 (0) 1 (0.8) 1.00 B
 Other 2 (3.6) 10 (7.9) 0.35 B
(n = 56) (n = 126)
Blood transfusion rate, n (%) 3 (5.4) 9 (7.1) 0.76 B
(n = 56) (n = 126)
Clavien grading score, n (%)
 None 40 (71.4) 82 (65.1) 0.51 A
 1 1 (1.8) 3 (2.4)
 2 11 (19.6) 18 (14.3)
 3a 2 (3.6) 14 (11.0)
 3b 2 (3.6) 5 (4.0)
 4a 0 (0) 3 (2.4)
 4b 0 (0) 0 (0)
 5 0 (0) 1 (0.8)
(n = 56) (n = 126)
Failed procedures 1 (1.8) 8 (6.4) 0.28 B
(n = 56) (n = 125)
Operation time (minutes), median, [IQR] 79.5, [62–101.5] 75, [57–94] 0.21 C
(n = 56) (n = 125)
Post-operative length of hospital stay (days), median, 
[IQR]
4, [3–5] 3, [2–4] 0.086 C
(n = 56) (n = 119)
Stone-free rate in follow-up 26 (50.0) 45 (38.5) 0.16 A
(n = 52) (n = 117)
Method of evaluation
 Computed tomography 11 (21.6) 20 (17.5) 0.33 A
 Ultrasound 35 (68.6) 70 (61.4)
 Retrograde pyelogram 0 (0) 2 (1.8)
 Intra-operative confirmation* 5 (9.8) 22 (19.3)
(n = 51) (n = 114)
Time until follow-up moment, weeks, median [IQR] 8 [12] 6 [4] 0.008 C
(n = 46) (n = 91)
Retreatment, n (%) 14 (25.5) 45 (36.0) 0.16 A
World J Urol 
1 3
their home institution. Visiting physicians’ anxiety levels 
were rated moderate by 29.8%, high by 25.0%, and very 
high by 17.9% of the respondents. Noteworthy, only 28.2% 
of the responders would let a visiting colleague operate on 
themselves or on a family member [3].
A tool that may contribute to patients’ safety is the more 
frequent use of ‘as live surgery’ (ALS) instead of LSDs. 
During ALS, the host and beholders can comment and 
debate ‘as live’ on a pre-recorded operation.
A survey study by Finch et al. was conducted on 165 
participants and evaluated patients’ safety, educational 
value, and ethical issues of ALS versus LSDs. Partici-
pants felt that there were significant patients’ safety ben-
efits with ALS over LSDs. In the same study, participants 
were significantly less likely to recommend participation 
in LSDs to family members or friends. Subsequently, they 
were significantly less likely to participate in an LSD set-
ting themselves [17]. A survey study by Phan et al. con-
cluded that the educational value of ALS is not inferior to 
LSD broadcasts. The majority of participants agreed that 
prior LSDs they watched were performed safely [6].
When organizing a live surgery event, organizers and 
participating physicians should adhere to a clearly defined 
regulatory framework. The ‘EAU live surgery code of con-
duct’ can contribute to the organisation of a safe event [1]. 
A final important aspect is patients’ safety. This does not 
only concern the physical safety during and after the sur-
gery, but also the respect of patients’ autonomy and pri-
vacy. Social media are an increasingly used medium to 
share knowledge. Regularly, patient’s image material is 
being shared. Even though the material is not traceable to 
the patient’s identity, it could contain information that the 
patient did not give permission to share on the World Wide 
Web. Everyone participating in LSDs should be aware of 
this and respect patients’ privacy.
This study supports the assumption that endourologi-
cal stone treatment during LSDs does not compromise 
patients’ safety. Still, caution should be exercised drawing 
a firm conclusion.
A limitation of this study is its retrospective design, 
which might have led to underestimating the complication 
rates. Furthermore, this is a single centre study with a 
restricted group of surgeons operating in a center that 
organized many LSD events in the studied years, making a 
routine of it for the local staff.
Even though it was not the objective of the present pro-
ject, it could be interesting to verify whether there is a dif-
ference in outcomes between local and visiting surgeons. 
In many of the procedures in this study, both a local and a 
visiting surgeon participated, e.g., ECIRS, so a subanaly-
sis with adequate statistical power was not implemented in 
this report. The majority of the procedures included in this 
study were performed by two experienced endourologists: 
one local and one visiting surgeon. Visiting surgeons were 
in the vast majority of the cases familiar with the circum-
stances, equipment and environment during LSDs. For this 
reason, the findings of this study may not directly assert for 
LSDs during larger conferences with a larger number of 
visiting surgeons.
Conclusion
The findings of this study indicate that live surgical dem-
onstrations for endourological stone removal do not com-
promise patients’ safety and outcomes when performed 
by specialised endourologists in a familiar setting. Either 
way, when performing LSDs, careful monitoring of out-
comes is a paramount consideration.
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